📰 Activating Construct News
Page 5 - Activating Construct News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Activating Construct. Real-time updates on events, politics, business and more.
June 4, 2021
Investegate announcements from Arix Bioscience PLC, Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting
June 4, 2021
DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO
June 4, 2021
DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO
June 4, 2021
Harpoon Therapeutics Inc (NASDAQ: HARP) has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating ...
March 11, 2021
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually ...
January 13, 2021
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma Harpoon Therapeutics, Inc. a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct targets B-cell maturation antigen a well-validated antigen expres...